ClinicalTrials.gg
CompletedNCT05727891ANUpdated Nov 20, 2026Results posted

Evaluation of Tonabersat for DME

A Phase 2 interventional study of Tonabersat and Placebo in Diabetic Macular Edema, sponsored by Jaeb Center for Health Research. Completed at 28 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Jaeb Center for Health Research · Phase 2, Interventional, and Treatment

How we know

Updated Nov 20, 2026Now CompletedResults posted+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
129
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 276 studies in Macular Edema with a site in United States — 16 open to participants now, 32 under way, 11 of them phase 3. Macular Edema · United States.

Enrollment
78th of 244
129 · median 45
Started
2023
with 10 others
Phase 2
63 of 276
3 open now
Registered
242nd of 276
by date
Lead sponsor
7 of 276
Jaeb Center for Health Research

Among the 276 studies in Macular Edema with a site in United States, this one is the 78th largest by enrollment of the 244 interventional ones that give a count, is one of 11 that started in 2023, is one of 63 in phase 2, and was the 242nd registered.

Macular Edema

759 studies on the registry are indexed under Macular Edema; 66 are open to participants now.

Browse Macular Edema studies →

Open to participants now

16 of the 276 studies in Macular Edema with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 276 studies in Macular Edema with a site in United States, or all of them as a file.
02

Study summary

This randomized clinical trial will evaluate the effect of tonabersat compared with placebo on central subfield thickness (CST) in eyes with center-involved diabetic macular edema (CI-DME) and good visual acuity.

Read the detailed description

The primary objective is to assess the effects of tonabersat, an orally administered Connexin43 hemichannel inhibitor, on central subfield thickness (mean change) compared with placebo in eyes with CI-DME and good visual acuity at 6 months.

Exploratory objectives will evaluate biomarkers of kidney function for potential benefit. Furthermore, this phase 2 study is being conducted to determine whether the conduct of a phase 3 trial has merit and provide information on outcome measures needed to design a phase 3 trial.

03

Conditions studied

  • Diabetic Macular Edema

Browse trials for

04

Who can participate

The criteria were revised on the registry on Nov 20, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria

  1. Adults with type 1 or 2 diabetes mellitus
  2. At least one eye with:

    • Best corrected Electronic-Early Treatment Diabetic Retinopathy Study visual acuity letter score ≥ 74 (i.e., 20/32 or better)
    • Ophthalmoscopic evidence of center-involved diabetic macular edema (CI-DME) in study eye confirmed by central subfield thickness on spectral domain optical coherence (OCT)
    • Zeiss Cirrus: ≥ 290 µm in females, ≥ 305 µm in males
    • Heidelberg Spectralis: ≥ 305 µm in females, ≥ 320 µm in males

      • Recruitment will be monitored with a goal to have equal proportions in the following categories above the CI-DME thresholds: \<75 μm, 75 μm to \<175 μm, ≥175 μm
  3. Media clarity, pupillary dilation, and study participant cooperation sufficient for adequate OCT

Key Exclusion Criteria

  • Macular edema is considered to be due to a cause other than diabetic macular edema (DME)
  • Major ocular surgery within the prior 4 months, or anticipated after randomization
  • History of focal/grid laser or other ocular surgical, intravitreal, or peribulbar treatment for DR or DME within prior 1 year, and no more than 4 anti-VEGF injections within prior 3 years
  • Anticipated need to treat DME or diabetic retinopathy during the first 6 months, or anticipated need for cataract surgery during study period
  • Any history of vitrectomy
  • Systemic anti-vascular endothelial growth factor (anti-VEGF) or pro-VEGF treatment within 12 months before randomization
  • History of chronic renal failure requiring dialysis or kidney transplant
  • History of moderate to severe hepatic impairment, including known liver function test (LFT) values > 3x's the
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
129 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Other: Placebo

  • Active comparator
    Tonabersat (80 mg)

    Drug: Tonabersat

Interventions

  • Two pills of Study Drug (80 mg tonabersat) is taken orally once daily. It is recommended the Study Drug be taken at bedtime. The first dose (two pills) will be taken at bedtime on the day the participant is randomized.

  • OtherPlacebo

    Two pills of Study Drug (placebo) is taken orally once daily. It is recommended the Study Drug be taken at bedtime. The first dose (two pills) will be taken at bedtime on the day the participant is randomized.

06

What researchers measure

Primary outcomes

  1. Optical Coherence Tomography Central Subfield Thickness Change From Baseline

    Measurements made on the Cirrus device were converted to equivalent measurements as would be assessed on the Spectralis device with the use of the following formula: Spectralis measurement = 40.78 + 0.95 × Cirrus measurement.

    Time frame: 6 months

Secondary outcomes

  1. Retinal Volume Change From Baseline

    Time frame: 6 months

  2. Optical Coherence Tomography Central Subfield Thickness Below the Sex-specific Threshold for Central-involved Diabetic Macular Edema and ≥10% Decrease in CST From Baseline to 6 Months

    CI-DME is indicated if Zeiss Cirrus CST: ≥290µm in females and ≥305µm in males or Heidelberg Spectralis CST: ≥305µm in females and ≥320µm in males; Multiple imputation was not performed given the thresholds are gender and machine specific.

    Time frame: 6 months

  3. Mean Change in Visual Acuity

    Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, \<20/800), with higher scores indicating better vision. The data presented are the best-corrected visual acuity in the study eye after protocol-defined refraction.

    Time frame: 6 months

  4. Received Other Treatment for Diabetic Macular Edema Prior to 6-month Visit

    Time frame: 6 months

  5. Received Anti-VEGF Treatment for Diabetic Macular Edema Prior to 6-month Visit

    anti-VEGF= antivascular endothelial growth factor

    Time frame: 6 months

07

Results

Posted Nov 20, 2026

Participant flow

Participant flow — Overall Study
MilestonePlaceboTonabersat (80 mg)
Started6564
Completed6061
Not completed53
Withdrew: Missed visit21
Withdrew: Withdrawal by subject21
Withdrew: Lost to follow-up01
Withdrew: Death10

Outcome measures

PrimaryOptical Coherence Tomography Central Subfield Thickness Change From Baseline

Measurements made on the Cirrus device were converted to equivalent measurements as would be assessed on the Spectralis device with the use of the following formula: Spectralis measurement = 40.78 + 0.95 × Cirrus measurement.

Time frame:
6 months
Reported as:
Mean · Microns
Optical Coherence Tomography Central Subfield Thickness Change From Baseline
MicronsPlaceboTonabersat (80 mg)
Optical Coherence Tomography Central Subfield Thickness Change From Baseline5 ± 51-15 ± 55
SecondaryRetinal Volume Change From Baseline
Time frame:
6 months
Reported as:
Mean · mm^3
Retinal Volume Change From Baseline
mm^3PlaceboTonabersat (80 mg)
Retinal Volume Change From Baseline0.03 ± 0.30-0.12 ± 0.42
SecondaryOptical Coherence Tomography Central Subfield Thickness Below the Sex-specific Threshold for Central-involved Diabetic Macular Edema and ≥10% Decrease in CST From Baseline to 6 Months

CI-DME is indicated if Zeiss Cirrus CST: ≥290µm in females and ≥305µm in males or Heidelberg Spectralis CST: ≥305µm in females and ≥320µm in males; Multiple imputation was not performed given the thresholds are gender and machine specific.

Time frame:
6 months
Reported as:
Count of units · Eyes
Optical Coherence Tomography Central Subfield Thickness Below the Sex-specific Threshold for Central-involved Diabetic Macular Edema and ≥10% Decrease in CST From Baseline to 6 Months
EyesPlaceboTonabersat (80 mg)
Optical Coherence Tomography Central Subfield Thickness Below the Sex-specific Threshold for Central-involved Diabetic Macular Edema and ≥10% Decrease in CST From Baseline to 6 Months38
SecondaryMean Change in Visual Acuity

Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, \<20/800), with higher scores indicating better vision. The data presented are the best-corrected visual acuity in the study eye after protocol-defined refraction.

Time frame:
6 months
Reported as:
Mean · Letter Score
Mean Change in Visual Acuity
Letter ScorePlaceboTonabersat (80 mg)
Mean Change in Visual Acuity-0.4 ± 5.70 ± 5.7
SecondaryReceived Other Treatment for Diabetic Macular Edema Prior to 6-month Visit
Time frame:
6 months
Reported as:
Count of units · Eyes
Received Other Treatment for Diabetic Macular Edema Prior to 6-month Visit
EyesPlaceboTonabersat (80 mg)
Received Other Treatment for Diabetic Macular Edema Prior to 6-month Visit54
SecondaryReceived Anti-VEGF Treatment for Diabetic Macular Edema Prior to 6-month Visit

anti-VEGF= antivascular endothelial growth factor

Time frame:
6 months
Reported as:
Count of units · Eyes
Received Anti-VEGF Treatment for Diabetic Macular Edema Prior to 6-month Visit
EyesPlaceboTonabersat (80 mg)
Received Anti-VEGF Treatment for Diabetic Macular Edema Prior to 6-month Visit74

Adverse events

Collected over 6 months. Non-serious events are listed at a 0.01% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo1/65 (1.5%)10/65 (15.4%)50/65 (76.9%)
Tonabersat (80 mg)0/64 (0%)14/64 (21.9%)46/64 (71.9%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventPlaceboTonabersat (80 mg)
Congestive heart failureCardiac disorders0/652/64
DizzinessNervous system disorders0/652/64
Atrial fibrillationCardiac disorders0/651/64
Cardiac arrhythmiaCardiac disorders0/651/64
Heart failureCardiac disorders1/651/64
TachycardiaCardiac disorders0/651/64
HypoglycemiaEndocrine disorders0/651/64
SepsisInfections and infestations0/651/64
Sacroiliac joint dysfunctionMusculoskeletal and connective tissue disorders0/651/64
Shoulder painMusculoskeletal and connective tissue disorders0/651/64
Most frequent other events
Showing 10 of 151
Most frequent other events
EventPlaceboTonabersat (80 mg)
DizzinessNervous system disorders7/6516/64
HeadacheNervous system disorders12/655/64
Urine albumin/creatinine ratio increasedInvestigations9/6510/64
DrowsinessNervous system disorders7/657/64
Diabetic macular edemaEye disorders7/653/64
ColdRespiratory, thoracic and mediastinal disorders2/656/64
C-reactive protein result highInvestigations6/654/64
Glucose highInvestigations2/655/64
Albumin increasedInvestigations5/651/64
NauseaGastrointestinal disorders1/654/64

Baseline characteristics

Units in Eyes: 7 participants in the Tonabersat group and 8 participants in the Placebo group enrolled in two study eyes

Age, Continuous
Age, Continuous(years)PlaceboTonabersat (80 mg)Total
Mean63 ± 1063 ± 1063 ± 10
Sex/Gender, Customized
Sex/Gender, Customized(Participants)PlaceboTonabersat (80 mg)Total
Female262248
Male394281
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboTonabersat (80 mg)Total
White424183
Black/African American101323
Hispanic or Latino12820
More than one race112
Unknown/not reported011
Type of diabetes
Type of diabetes(Participants)PlaceboTonabersat (80 mg)Total
Type 1325
Type 26262124
Duration of diabetes
Duration of diabetes(years)PlaceboTonabersat (80 mg)Total
Mean16 ± 1119 ± 1017 ± 11
Glycated hemoglobin
Glycated hemoglobin(Hemoglobin A1c percentage)PlaceboTonabersat (80 mg)Total
Mean7.5 ± 1.27.1 ± 1.27.3 ± 1.2
Visual acuity letter score
Visual acuity letter score(Letter Score)PlaceboTonabersat (80 mg)Total
Mean83 ± 484 ± 483 ± 4
Central subfield thickness
Central subfield thickness(Microns)PlaceboTonabersat (80 mg)Total
Mean362 ± 59359 ± 63360 ± 61

3 further baseline measures are reported on the registry.

08

Study locations

28 sites
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Jan 2026, 32 months.

Results were first posted in Nov 2026, 10 months after primary completion.

Of 50 phase 2 interventional studies under Macular Edema, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 32. This study's 32 months is above that.

Primary completion moved once since we started tracking on Sep 25, 2026: Jun 2025 → Jan 2026, on Nov 20, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2023
First posted
Feb 14, 2023
StartActual
May 2, 2023
Primary completionActual
Jan 15, 2026was Jun 2025
CompletionActual
Jan 15, 2026
Results first posted
Nov 20, 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 20, 2026
Results
Results posted
posted Nov 20, 2026
Primary completion
Jun 27, 2025→Jan 15, 2026
Nov 20, 2026
Enrollment
128 (estimated)→129 (actual)
Nov 20, 2026
Eligibility
6 criteria edited
What changed in the criteria
  • EditedBest corrected EElectronic-ETDRSEarly Treatment Diabetic Retinopathy Study visual acuity letter score ≥ 74 (i.e., 20/32 or better)
  • EditedOphthalmoscopic evidence of center-involved diabetic macular edema (CI-DME) in study eye confirmed by central subfield thickness on spectral domain optical coherence (OCT)
  • EditedMacular edema is considered to be due to a cause other than diabetic macular edema (DME)
  • EditedMajor ocular surgery within the prior 4 months, or anticipated after randomization
  • EditedAnticipated need to treat DME or DRdiabetic retinopathy during the first 6 months, or anticipated need for cataract surgery during study period
  • EditedSystemic anti-vascular endothelial growth factor (anti-VEGF) or pro-VEGF treatment within 12 months prior tobefore randomization
Nov 20, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Mean change in central subfield thicknessNow Optical Coherence Tomography Central Subfield Thickness Change From BaselineTime frame: 6 months
Nov 20, 2026
Documents
Secondary outcomes
4 edited, 1 added
What changed in the outcomes
  • EditedMean change in retinal volume from baselineRetinal Volume Change From BaselineTime frame: 6 months
  • EditedPercentage of eyes central subfield thickness below optical coherence machineOptical Coherence Tomography Central Subfield Thickness Below the Sex-specific Threshold for Central-involved Diabetic Macular Edema and sex-specific threshold for DME and at least a ≥10% decrease from baselineDecrease in CST From Baseline to 6 MonthsTime frame: 6 months
  • EditedMean changeChange in visual acuity from baselineVisual AcuityTime frame: 6 months
  • EditedPercentage of eyes receiving other treatmentReceived Other Treatment for DME priorDiabetic Macular Edema Prior to the 6 -month visitVisitTime frame: 6 months
  • AddedReceived Anti-VEGF Treatment for Diabetic Macular Edema Prior to 6-month VisitTime frame: 6 months
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Active, not recruiting→Completed
    Results posted
    Primary completion Jun 27, 2025→Jan 15, 2026
    Enrollment 128 (estimated)→129 (actual)
    Eligibility 6 criteria edited
    What changed in the criteria
    • EditedBest corrected EElectronic-ETDRSEarly Treatment Diabetic Retinopathy Study visual acuity letter score ≥ 74 (i.e., 20/32 or better)
    • EditedOphthalmoscopic evidence of center-involved diabetic macular edema (CI-DME) in study eye confirmed by central subfield thickness on spectral domain optical coherence (OCT)
    • EditedMacular edema is considered to be due to a cause other than diabetic macular edema (DME)
    • EditedMajor ocular surgery within the prior 4 months, or anticipated after randomization
    • EditedAnticipated need to treat DME or DRdiabetic retinopathy during the first 6 months, or anticipated need for cataract surgery during study period
    • EditedSystemic anti-vascular endothelial growth factor (anti-VEGF) or pro-VEGF treatment within 12 months prior tobefore randomization
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Mean change in central subfield thicknessNow Optical Coherence Tomography Central Subfield Thickness Change From BaselineTime frame: 6 months
    Secondary outcomes 4 edited, 1 added
    What changed in the outcomes
    • EditedMean change in retinal volume from baselineRetinal Volume Change From BaselineTime frame: 6 months
    • EditedPercentage of eyes central subfield thickness below optical coherence machineOptical Coherence Tomography Central Subfield Thickness Below the Sex-specific Threshold for Central-involved Diabetic Macular Edema and sex-specific threshold for DME and at least a ≥10% decrease from baselineDecrease in CST From Baseline to 6 MonthsTime frame: 6 months
    • EditedMean changeChange in visual acuity from baselineVisual AcuityTime frame: 6 months
    • EditedPercentage of eyes receiving other treatmentReceived Other Treatment for DME priorDiabetic Macular Edema Prior to the 6 -month visitVisitTime frame: 6 months
    • AddedReceived Anti-VEGF Treatment for Diabetic Macular Edema Prior to 6-month VisitTime frame: 6 months
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05727891
Collaborators
National Institutes of Health (NIH), National Eye Institute (NEI), Juvenile Diabetes Research Foundation
Responsible party
Sponsor
First posted
Feb 14, 2023
Start date
May 2, 2023
Primary completion
Jan 15, 2026
Completion
Jan 15, 2026
Results posted
Nov 20, 2026
Last update
Nov 20, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tonabersat

Start the discussion